PRESS RELEASE: SphingoTec Expands Management Team and Appoints new CFO

06/10/2021 | 04:01am
DGAP-News: SphingoTec GmbH / Key word(s): Corporate Action/Strategic Company Decision 
SphingoTec Expands Management Team and Appoints new CFO 
2021-06-10 / 10:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
  . Dr. Angelo Moesslang was named CFO and Managing Director of SphingoTec. 
  . The company has developed innovative biomarkers for critical care settings and makes them available on their point 
    of care platform, Nexus IB10. 
  . The new senior leadership addition broadens SphingoTec's core capabilities in response to the anticipated 
    significant expansion of its activities. 
Hennigsdorf/Berlin, Germany, June 10, 2021 - Diagnostics company SphingoTec GmbH ("SphingoTec") announces the 
appointment of Dr. Angelo Moesslang as new chief financial officer (CFO) and managing director. 
SphingoTec develops and markets innovative in vitro diagnostic solutions for novel biomarkers that support personalized 
medicine in critical care conditions. Sphingotec is a fully integrated diagnostics company: the innovative biomarkers 
are commercially available on the proprietary point of care platform Nexus IB10. Following a successful implementation 
of the biomarkers in clinical routine, the company is now oriented towards geographical expansion and commercial 
growth. 
Dr. Angelo Moesslang commented, "I was drawn to SphingoTec's vision and focus of translating the science of novel 
biomarkers into clinical routine. I am excited to join such an innovative young company, ideally positioned for growth. 
This new role will allow me to leverage my expertise, contribute to the commercialization effort and continue the 
initiatives of improving patient management in critical care with innovative diagnostic solutions." 
Dr. Moesslang has more than 20 years of global healthcare and finance leadership experience. Prior to joining 
SphingoTec he served as CEO of a US-based medical device startup and held various executive roles with the Fresenius 
Group in Europe, Asia, and the US, most recently CFO of Fresenius Medical Care North America. 
Dr. Andreas Bergmann, CEO and founder of SphingoTec added, "With the international commercialization of our validated 
biomarkers and established point of care platform, we are now bringing diagnostic breakthroughs to critical care 
clinicians. We are excited to welcome Mr. Moesslang, whose entrepreneurial spirit and energy will bring strategic value 
to our next stage of business development. " 
About SphingoTec 
SphingoTec GmbH ("SphingoTec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in vitro diagnostic 
(IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical 
conditions. SphingoTec's proprietary biomarker portfolio includes bioactive Adrenomedullin (bio-ADM), a unique 
biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, 
Proenkephalin (penKid), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 
(DPP3), a unique biomarker for cardiac depression. IVD tests for SphingoTec's proprietary biomarkers are made available 
as sphingotest(R) microtiter plate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform. 
SphingoTec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) produces the tests alongside a broad menu of established and 
commonly used tests for acute and critical care. 
Contact 
Ruxandra Lenz 
Sr. Manager Marketing and Communications 
SphingoTec GmbH 
Neuendorfstr. 15 A 
16761 Hennigsdorf 
Tel. +49-3302-20565-0 
press@sphingotec.com 
www.sphingotec.com 
 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-10 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 

1206336 2021-06-10

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1206336&application_name=news 
 

(END) Dow Jones Newswires

June 10, 2021 04:00 ET (08:00 GMT)

Copier lien
Latest news about "Companies"
2m ago
46m ago
46m ago
1h ago
1h ago